58 completed, 5 terminated, 4 active not recruiting, 4 unknown. 76 Phase 2, 10 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 76 | Completed 58, Terminated 5, Active not recruiting 4, Unknown 4, Withdrawn 3, Recruiting 2 |
| Phase 1 | 10 | Completed 9, Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow HIV-1 Infection: new trials by email Literature Review of HIV-1 Infection trials Research Report on HIV-1 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels B/F/TAF, GS-3242, Lenacapavir - HIV-1 Infection | Phase 2 | Recruiting | Gilead Sciences | 125 | 2026-10-01 | 2026-10-23 |
| A Phase Ⅱa Clinical Study of CL-197 Capsules CL-197 capsules - HIV-1 Infection | Phase 2 | Recruiting | Henan Genuine Biotech Co., Ltd. | 24 | 2025-11-29 | 2026-01-06 |
| A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection UB-421 - Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-07-10 | 2025-07-11 | |
| Pomalidomide as an Immune-enhancing Agent for the Control of HIV Pomalidomide 2 mg, Placebo, Aspirin 75 mg - HIV-1 Infection | Phase 1 / Phase 2 | Active not recruiting | University of Aarhus | 32 | 2025-05-13 | 2026-05-07 |
| UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients UB-421, Optimized background therapy (OBT) - HIV-1 Infection | Phase 2 | Unknown | United BioPharma | 10 | 2023-12-01 | 2023-04-24 |
| A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection Teropavimab, Zinlirvimab, Lenacapavir Tablet - HIV-1 Infection | Phase 2 | Active not recruiting | Gilead Sciences | 83 | 2023-05-15 | 2026-04-27 |
| A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs UB-421, chidamide - HIV-1 Infection | Phase 2 | Completed | United BioPharma | 11 | 2021-12-02 | 2023-02-15 |
| Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV ISL, LEN, B/F/TAF - HIV-1 Infection | Phase 2 | Active not recruiting | Gilead Sciences | 142 | 2021-10-05 | 2026-02-04 |
| Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] Islatravir, Ulonivirine, BIC/FTC/TAF - HIV-1 Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 161 | 2021-03-09 | 2026-01-26 |
| Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028) DOR/ISL - HIV-1 Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 42 | 2020-11-26 | 2024-01-31 |
| the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients UB-421, Antiretroviral Therapy (ART) - HIV-1 Infection | Phase 2 | Withdrawn | United BioPharma | 2020-04-01 | 2020-02-21 | |
| Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) Islatravir, Placebo - HIV-1 Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 242 | 2019-09-19 | 2025-07-18 |
| A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma Cal-1 (LVsh5/C46) drug product - HIV-1 Infection | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 2 | 2019-01-15 | 2025-11-20 |
| The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W - HIV-1 Infection | Phase 2 | Completed | United BioPharma | 31 | 2018-12-12 | 2022-05-13 |
| Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) Islatravir, Placebo to Islatravir, Doravirine - HIV-1 Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 123 | 2017-11-27 | 2023-03-29 |
| Early ART to Limit Infection and Establishment of Reservoir elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy - HIV-1 Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 195 | 2017-01-24 | 2025-08-29 |
| Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS) - HIV-1 Infection | Phase 2 / Phase 3 | Active not recruiting | Gilead Sciences | 177 | 2016-09-21 | 2026-09-24 |
| Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers Visbiome Extra Strength, Placebo - HIV-1 Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 93 | 2016-04-01 | 2020-01-06 |
| 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF Ledipasvir/sofosbuvir, Ribavirin - HIV-1 Infection, Hepatitis C | Phase 2 | Terminated | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 7 | 2016-02-17 | 2018-05-02 |
| Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) Doravirine/lamivudine/tenofovir disoproxil fumarate - HIV-1 Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 10 | 2016-01-14 | 2021-10-26 |
Showing 20 of 76. Sign in to see all of them.
Infections (4) · HIV Infections (3) · Acquired Immunodeficiency Syndrome (2) · Hepatitis C (2) · Inflammation (2) · Cardiovascular Diseases (1) · Lymphoma (1) · Thrombosis (1) · Tuberculosis (1)
Blood-Borne Infections (7) · Communicable Diseases (7) · Infections (7) · RNA Virus Infections (7) · Virus Diseases (7) · Immune System Diseases (6) · Genital Diseases (5) · Immunologic Deficiency Syndromes (5) · Lentivirus Infections (5) · Retroviridae Infections (5) · Sexually Transmitted Diseases (5) · Sexually Transmitted Diseases, Viral (5) · Urogenital Diseases (5) · Digestive System Diseases (2) · Flaviviridae Infections (2)
Ritonavir (8) · Lamivudine (7) · UB-421 (6) · bictegravir, emtricitabine, tenofovir alafenamide, drug combination (5) · dolutegravir (5) · efavirenz (5) · Aspirin (4) · Atazanavir Sulfate (4) · Darunavir (4) · islatravir (4) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (3) · Tenofovir (3) · doravirine (3) · lenacapavir (3) · 3BNC117 antibody (2)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (20) · Gilead Sciences (8) · ANRS, Emerging Infectious Diseases (5) · Merck Sharp & Dohme LLC (5) · United BioPharma (5) · Bionor Immuno AS (3) · Rockefeller University (2) · Tobira Therapeutics, Inc. (2) · University Health Network, Toronto (2) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · Castagna Antonella (1) · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida (1) · GlaxoSmithKline (1) · Henan Genuine Biotech Co., Ltd. (1)
United States (44) · France (16) · Puerto Rico (13) · South Africa (7) · Canada (6) · Italy (5) · Spain (5) · Thailand (5) · United Kingdom (5) · Australia (4) · Germany (4) · Kenya (3) · Peru (3) · Taiwan (3) · Botswana (2)
Christine Katlama, MD (2) · Marina Caskey, MD (2) · Meagan O'Brien, MD (2) · Netanya Sandler, MD (2) · Rajesh Gandhi, MD (2) · Rupert Kaul, MD (2) · Adriana Andrade, MD, MPH (1) · Adriano Lazzarin, Prof (1) · Allan R. Tenorio, M.D. (1) · Amneris E Luque, M.D. (1) · Andrew Beelen, MD (1) · Annie Luetkemeyer, MD (1) · Babafemi Taiwo, MBBS (1)
PMID 20710052, PMID 21317794, PMID 21486960, PMID 21811136, PMID 22837004, PMID 23797691, PMID 23830355, PMID 23875707, PMID 24446523, PMID 24620025, PMID 24864123, PMID 25214516, PMID 25624326, PMID 25979307, PMID 26060295, PMID 26075752, PMID 26271944, PMID 26636929, PMID 26684819, PMID 26762988, PMID 27077673, PMID 27965866, PMID 28219610, PMID 28340570, PMID 28714868, PMID 28832406, PMID 29091342, PMID 29253097, PMID 29794828, PMID 30239650, PMID 30535188, PMID 30668695, PMID 30699178, PMID 30830886, PMID 30995373, PMID 31085814, PMID 31425317, PMID 31498109, PMID 31504342, PMID 32661003, PMID 33323024, PMID 33382405, PMID 33540481, PMID 33568510, PMID 34000227, PMID 34049356, PMID 34302760, PMID 34369424, PMID 34693932, PMID 34693933
U01AI068636 (10), UM1AI068636 (7), 2015 (3), 2UM1AI068636 (3), 2019 (2), 2008 (1), 2009 (1), 2014 (1), 2016 (1), 2017 (1), R01AI066992 (1), R56HL127995 (1), U01AI095052 (1), U01AI118536 (1)